Skip to content

Search

JDRF podcast with Liz

Have you had the chance to listen in on JDRF Australia’s T1D Tune In interview with Professor Liz Davis?

Access to the new Dexcom G6 sensor

Perth Children’s Hospital’s Diabetes Clinic has had a few queries about the new Dexcom G6 sensor, which recently became available in Australia.

Mark Shah wins award

Congratulations to PCH Nurse Practitioner Mark Shah, winner of the WA and Australian Credential Diabetes Educator of the Year awards 2021.

New Study: Water Survey UWA

There is evidence that physical activity is well known to increase the risk of hypoglycaemia in people with type 1 diabetes. However, little is known about the effect of water-based activities on blood glucose levels.

Dexcom G6 Early Access Program Update

The Dexcom G6 Early Access Program has so far been a huge success. The program commenced in May, and offered early access to the Dexcom G6 system to eligible patients.

Congratulations Seed Funding Recipients!

The Rio Tinto Children’s Diabetes Centre; a JDRF Global Centre of Excellence announces inaugural funding for researchers dedicated to type 1 diabetes.

Training vs competition blood glucose in people with type 1 diabetes

Participants needed for a research study to observe the influence of competition stress on the blood glucose and management strategies of people with T1D

DiabHQ is on the way

Over the coming months, WA children living with diabetes will be given the opportunity to participate in DiabHQ, an innovative new data platform.

WANdiab patient management system upgrade

We've updated our clinical diabetes patient management system to a new state-of-the art system that can access critical informtion in real-time during clinic. 

Disparities in Diabetes Technology Uptake in Youth and Young Adults With Type 1 Diabetes: A Global Perspective

Globally, nearly 9 million people are living with type 1 diabetes (T1D). Although the incidence of T1D is not affected by socioeconomic status, the development of complications and limited access to modern therapy is overrepresented in vulnerable populations. Diabetes technology, specifically continuous glucose monitoring and automated insulin delivery systems, are considered the gold standard for management of T1D, yet access to these technologies varies widely across countries and regions, and varies widely even within high-income countries.